Guidelines Panel Meeting: Early Detection of Prostate Cancer (2022)
Panel members will be reviewing evidence prepared and presented by a methodologist who has been extracting and analyzing data from research articles. The panelists will inquire about aspects of the evidence and the methodologist will provide explanations. The panel will discuss the evidence and deliberate on the best practice methods to detect early stages of prostate cancer.
Target Audience
This activity is limited to Early Detection of Prostate Cancer Guidelines Panel Members only.
Learning Objectives
After completing this activity, participants will be able to:
- Analyze the latest scientific evidence for early detection of prostate cancer.
- Recommend appropriate screening methods for detecting prostate cancer at an early stage.
- Apply improved critical thinking skills to medical literature reviews.
Thursday, September 1, 2022
6:00-6:10pm Welcome and Introductions Sennett Kim
6:10-6:20pm Conflict of Interest Disclosures and Panel Responsibilities Sennett Kim
6:20-8:45pm EDPC Evidence Overview Lesley Souter
8:45-9:00pm Questions/Comments
Monday, September 12, 2022
6:00-6:15pm Introduction to review of Statement Development Dr. Wei, MD
6:15-8:45pm Guideline Statement Development Panel
8:45-9:00pm Questions/Comments
Wednesday, September 14, 2022
6:00-8:45pm Continue Guideline Statement Development Panel
8:45-9:00pm Questions/Comments and Next Steps
Thursday, September 29, 2022
6:00-7:45pm Continue working on remaining statements Panel
7:45-8:00pm Working groups to provide updates on writing Panel
and address questions for the chairs
*All Eastern Time
The Early Detection of Prostate Cancer Guidelines Panel have the following disclosures.
Name | Company Name | Role | Financial | End Date |
Barocas, Daniel Ari | Ambu | Meeting Participant or Lecturer | Yes | 04/26/2022 |
Barocas, Daniel Ari | lantheus | Meeting Participant or Lecturer | Yes | 11/30/2022 |
Barocas, Daniel Ari | Pacific Edge Diagnostics | Meeting Participant or Lecturer | Yes | 12/01/2022 |
Barocas, Daniel Ari | Optum Health | Consultant or Advisor | Yes | Current |
Carlsson, Sigrid Viktoria | National Institutes of Health/National Cancer Inst | Other-Research Funding | Yes | Current |
Carlsson, Sigrid Viktoria | Prevent Cancer Foundation | Consultant or Advisor | No | Current |
Carlsson, Sigrid Viktoria | Studentlitteratur AB | Health Publishing | Yes | Current |
Carlsson, Sigrid Viktoria | National Comprehensive Cancer Network (NCCN) | Other-National Comprehensive Cancer Network Prostate Cancer Early Detection Guideline panel member | No | Current |
Carlsson, Sigrid Viktoria | British Journal of Urology International (BJUI) | Health Publishing | Yes | Current |
Carlsson, Sigrid Viktoria | Journal of Sexual Medicine (JSM) | Health Publishing | Yes | Current |
Carlsson, Sigrid Viktoria | Patient Centered Outcomes Research Institute PCORI | Other-Research Funding | Yes | 08/31/2021 |
Carlsson, Sigrid Viktoria | AUA | Consultant or Advisor | No | Current |
Carlsson, Sigrid Viktoria | Weill Cornell Medicine | Meeting Participant or Lecturer | Yes | 08/18/2021 |
Carlsson, Sigrid Viktoria | The Chinese University of Hong Kong | Meeting Participant or Lecturer | Yes | 10/30/2021 |
Carlsson, Sigrid Viktoria | Mediahuset Gothenburg Sweden | Meeting Participant or Lecturer | Yes | 09/17/2021 |
Coakley, Fergus | OmnEcoil Instruments, Inc. | Owner | Yes | Current |
Eggener, Scott E. | Profound Medical | Consultant or Advisor | Yes | Current |
Eggener, Scott E. | janssen | Meeting Participant or Lecturer | Yes | Current |
Eggener, Scott E. | Insightec | Consultant or Advisor | Yes | Current |
Eggener, Scott E. | ASCO | Health Publishing | No | Current |
Eggener, Scott E. | Francis Medical | Meeting Participant or Lecturer | Yes | Current |
Eggener, Scott E. | Candel | Scientific Study or Trial | No | Current |
Eggener, Scott E. | CellVax | Consultant or Advisor | Yes | Current |
Eggener, Scott E. | MetasTx | Consultant or Advisor | Yes | Current |
Etzioni, Ruth | Nothing to disclose | |||
Fine, Samson William | Nothing to disclose | |||
Han, Misop | Eigen | Other-Patent licensed | Yes | Current |
Han, Misop | NIH | Scientific Study or Trial | No | 02/19/2026 |
Kim, Sennett | Nothing to disclose | |||
Konety, Badrinath R. | FKD Therapeutics | Scientific Study or Trial | Yes | 06/30/2021 |
Konety, Badrinath R. | Bristol Myers Squibb | Scientific Study or Trial | No | Current |
Konety, Badrinath R. | Boston Scientific Corp | Consultant or Advisor | Yes | 12/31/2021 |
Konety, Badrinath R. | Merck Inc | Scientific Study or Trial | Yes | 06/03/2021 |
Konety, Badrinath R. | Francis Medical | Consultant or Advisor | Yes | 05/03/2021 |
Konety, Badrinath R. | Convergent genomics | Consultant or Advisor | Yes | Current |
Konety, Badrinath R. | FerGene Inc | Consultant or Advisor | Yes | 11/30/2020 |
Konety, Badrinath R. | Nucleix Inc | Consultant or Advisor | Yes | 11/30/2020 |
Konety, Badrinath R. | Photocure | Consultant or Advisor | Yes | Current |
Konety, Badrinath R. | Astrin Biosciences | Consultant or Advisor | Yes | Current |
Konety, Badrinath R. | Styx Biotechnology | Investment Interest | Yes | Current |
Lin, Daniel Wei | NIH/NCI | Scientific Study or Trial | Yes | Current |
Lin, Daniel Wei | Department of Defense | Scientific Study or Trial | Yes | Current |
Lin, Daniel Wei | Genomic Health, Inc. | Scientific Study or Trial | Yes | 12/31/2020 |
Lin, Daniel Wei | GenomeDx | Scientific Study or Trial | No | 12/31/2020 |
Lin, Daniel Wei | Astellas | Consultant or Advisor | No | Current |
Lin, Daniel Wei | MDxHealth | Scientific Study or Trial | No | Current |
Lin, Daniel Wei | Clovis Oncology | Consultant or Advisor | Yes | Current |
Lin, Daniel Wei | MagForce USA | Scientific Study or Trial | Yes | Current |
Miner, Martin M. | Antares | Consultant or Advisor | No | 06/01/2021 |
Miner, Martin M. | Clarus | Consultant or Advisor | Yes | 08/30/2022 |
Miner, Martin M. | Lipocine | Health Publishing | No | 01/01/2022 |
Miner, Martin M. | Acerus | Consultant or Advisor | Yes | Current |
Miner, Martin M. | Halozyme | Consultant or Advisor | Yes | Current |
Moses, Kelvin A. | Astellas | Consultant or Advisor | Yes | 07/01/2021 |
Moses, Kelvin A. | Dendreon | Scientific Study or Trial | Yes | 01/01/2021 |
Moses, Kelvin A. | Pfizer | Consultant or Advisor | Yes | 07/01/2021 |
Moses, Kelvin A. | Pfizer | Scientific Study or Trial | No | 01/01/2021 |
Moses, Kelvin A. | Janssen | Scientific Study or Trial | No | 01/01/2021 |
Nissenberg, Merel G. | Nothing to disclose | |||
Pinto, Peter Anthony | Philips/InVivo Inc | Other | Yes | Current |
Salami, Simpa Samuel | Nothing to disclose | |||
Souter, Lesley | Nothing to disclose | |||
Thompson Jr., Ian Murchie | SWOG | Leadership Position | No | Current |
Thompson Jr., Ian Murchie | MagForce | Consultant or Advisor | Yes | Current |
Thompson Jr., Ian Murchie | Threshold | Consultant or Advisor | Yes | 06/25/2022 |
Thompson Jr., Ian Murchie | Harvard University | Consultant or Advisor | Yes | Current |
Thompson Jr., Ian Murchie | H-E-B (grocery store chain) | Leadership Position | Yes | Current |
Thompson Jr., Ian Murchie | NIH/NCI U01 Grant | Scientific Study or Trial | Yes | Current |
Wei, John Thomas | NCI | Other | No | Current |
Wei, John Thomas | Sanofi | Consultant or Advisor | Yes | 08/15/2021 |
AUA Staff have nothing to disclose.
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: The American Urological Association designates this live activity for a maximum of 11.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:
- Peer review for valid, evidence-based content by the AUA COI Review Work Group.
- Attestation that clinical recommendations are evidence-based and free of commercial bias.
- Introduction of a debate format (point-counterpoint)
- Inclusion of moderated panel discussion with unbiased moderator
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Divestiture of the relationship by faculty
- Recusal from controlling relevant aspects of planning
- Selection of alternative faculty for specific topic
Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
Available Credit
- 11.00 AMA PRA Category 1 Credit™
- 11.00 Non-Physician Participation